A Comprehensive Cardiovascular-Renal-Metabolic Risk Reduction Approach to Patients with Type 2 Diabetes Mellitus - 28/08/21

Abstract |
Despite decades of research into risk-reduction strategies, cardiovascular disease and renal disease remain leading causes of morbidity and mortality among patients with type 2 diabetes mellitus. Given the tight clustering of cardiovascular and renal disease with the metabolic abnormalities of type 2 diabetes mellitus, we can think of these conditions together as cardiovascular-renal-metabolic disease states. A holistic view of cardiovascular-renal-metabolic disease states is critical to provide integrated patient-centered care to individuals with these disease states. Here, we explore the cardiovascular and renal risks associated with type 2 diabetes mellitus and highlight the importance of reducing cardiovascular-renal-metabolic disease risk in a comprehensive manner. We advocate a cross-disciplinary, team-based model to manage cardiovascular-renal-metabolic disease risk among patients with type 2 diabetes mellitus.
Le texte complet de cet article est disponible en PDF.Keywords : Cardiovascular, Diabetes mellitus, Patient-centered, Prevention, Risk reduction
Plan
| Funding: None. |
|
| Conflicts of Interest: NJP reports research grants from Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Regeneron, Sanofi, Verily Life Sciences, and Novartis; consulting fees from Boehringer Ingelheim, Eli Lilly, AstraZeneca, and Novo Nordisk; and being on a study board for Novo Nordisk. PD reports research grants from Boehringer Ingelheim, Novartis, and Sanofi. |
|
| Authorship: Both authors drafted and critically revised the manuscript. |
Vol 134 - N° 9
P. 1076-1084 - septembre 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
